ClinicalTrials.gg
CompletedNCT03075462Updated Jul 1, 2022

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

A Phase 1 interventional study of Fluzoparib and Apatinib in Ovarian Cancer and Triple Negative Breast Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-07-01.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing fluzoparib in Ovarian Neoplasms — 13 open to participants now, 13 under way, 1 of them phase 3. fluzoparib · Ovarian Neoplasms.

Enrollment
9th of 22
98 · median 70
Started
2017
the only one that year
Phase 1
4 of 22
none open now
Registered
2nd of 22
by date
Lead sponsor
7 of 22
Jiangsu HengRui Medicine Co., Ltd.

Among the 22 studies testing fluzoparib in Ovarian Neoplasms, this one is the 9th largest by enrollment, is the only one that started in 2017, is one of 4 in phase 1, and was the 2nd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 22 studies testing fluzoparib in Ovarian Neoplasms are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

About fluzoparib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing fluzoparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

Fluzoparib is an oral potent, selective poly-ADP ribose polymerase-1 (PARP-1) and PARP-2 inhibitor; Apatinib is an oral selective vascular endothelial growth factor receptor (VEGFR) inhibitor. This open-label, dose finding phase I trial studies the tolerability and the best dose of fluzoparib in combination with apatinib and to see how well these two drugs work together in the treatment of patients with recurrent ovarian cancer or triple negative breast cancer. The safety and efficacy of fluzoparib in combination with apatinib will be explored. Both dose escalation and dose expansion parts are included in this study.

03

Conditions studied

  • Ovarian Cancer
  • Triple Negative Breast Cancer

Keywords

  • PARP inhibitor
  • VEGFR inhibitor
  • Combination therapy
  • Ovarian Cancer
  • Triple Negative Breast Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status of 0 to 1.
  • of more than 12 weeks.
  • or cytologically confirmed high-grade papillary-serous epithelial ovarian cancer,primary peritoneal, or fallopian tube cancers; subjects with a known deleterious breast cancer gene (BRCA) mutation and any other high-grade histology are also eligible. Subjects should have platinum-sensitive disease, where platinum-sensitive disease is defined as having had a > 6 month interval since last receiving platinum therapy prior to disease recurrence. Additionally, subjects with histologically or cytologically confirmed triple negative breast cancer (TNBC), that is locally advanced or , are also eligible.
  • Prior therapy:subjects with ovarian cancer,primary peritoneal, or fallopian tube cancers have received only 2 lines of platinum-based chemotherapies, and TNBC patients have received only 1 line of standard chemotherapy. Each prior chemotherapy must be given for at least 2 cycles.
  • At least one that can be accurately assessed by imaging (CT/MRI) at baseline
  • Subjects who have overall good overall general condition.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Subjects who received any previous treatment with any PARP inhibitors.
  • Subjects who received any previous treatment with any VEGFR inhibitors.
  • Less than 4 weeks from the last clinical trial.
  • Less than 4 weeks from the last radiotherapy, chemotherapy, surgery, hormone treatment and target therapy.
  • Unstable or uncontrolled hypertension.
  • Subjects that are unable to swallow, or dysfunction of gastrointestinal absorption.
  • Subjects with .
  • Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry.
  • Subjects with a known to fluzoparib, apatinib or any of the of the products.
  • Ongoing infection (determined by investigator).
  • History of immunodeficiency, including -positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation.
  • Pregnant or breast-feeding women.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Fluzoparib + Apatinib

    Fluzoparib and apatinib will be separately administered to patients on the 1st and 4th day, respectively. Then from the 7th day they are administered continuously and orally in combination, 28 days per cycle, until disease progression or unacceptable toxicity.

    Drug: Fluzoparib · Drug: Apatinib

Interventions

  • Fluzoparib either at 40,60,80mg twice daily,capsule oral.

    Also known as: SHR3162, HS10160

  • Apatinib at 250mg once daily, tablet oral

06

What researchers measure

Primary outcomes

  1. The type and incidence of adverse events [safety and tolerability]

    Adverse events defined according to Common Terminology for Adverse Events (CTCAE) v4.03

    Time frame: From screening up to 28 days after end of treatment

Secondary outcomes

  1. Objective Response Rate (ORR)

    \[Complete response + Partial response (CR+PR)\] based on RECIST 1.1

    Time frame: 24 months (approx) from the start of treatment

  2. Disease Control Rate (DOR)

    \[Complete response + Partial response + Stable disease (CR+PR+SD)\] based on RECIST 1.1

    Time frame: 24 months (approx) from the start of treatment

  3. Time to Progression (TTP)

    The time from start of the treatment until radiographic disease progression or CA-125 progression specific for ovarian cancer patients

    Time frame: From date of enrollment until the date of first objective progression or CA-125 progression (only for ovarian cancer patients), assessed up to 36 months

  4. Overall Survival (OS)

    Time from start of fluzoparib treatment until death due to any cause

    Time frame: From Cycle 1, Day 1 until death or up to 48 months (approx)

  5. Cmax

    Maximum Plasma Concentration

    Time frame: From the start of fluzoparib treatment alone to Cycle 2, Day 1 of combined treatment

  6. T1/2 (Half-life)

    The time required for the plasma concentration of a drug to be reduced by 50%

    Time frame: From the start of fluzoparib treatment alone to Cycle 2, Day 1 of combined treatment

  7. Area under curve (AUC)

    Area under the plasma concentration-time curve

    Time frame: Within the first 5 weeks from start of fluzoparib treatment

  8. V/F

    Volume of distribution

    Time frame: From the start of fluzoparib treatment alone to Cycle 2, Day 1 of combined treatment

  9. CL/F

    Plasma Clearance

    Time frame: From the start of fluzoparib treatment alone to Cycle 2, Day 1 of combined treatment

07

Study locations

1 site
  • Beijing Cancer Hosptial
    Beijing, Beijing 100142, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Aug 2021, 53 months.

Of 210 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 53 months is above that.

Counting every sponsor, half of 380 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2017
First posted
Mar 9, 2017
StartActual
Mar 9, 2017
Primary completionActual
Aug 22, 2021
CompletionActual
Dec 13, 2021
Last update
Jul 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03075462
Responsible party
Sponsor
First posted
Mar 9, 2017
Start date
Mar 9, 2017
Primary completion
Aug 22, 2021
Completion
Dec 13, 2021
Last update
Jul 1, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluzoparib · Apatinib

Start the discussion